Physician profile
Michael Littner
NPI 1184071649
$7,018.65
in general payments reported to CMS, 2019-2025
25 companies · $3,823 in 2025
The $3,823 reported for 2025 was more than what 98% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $395 · 2024: $2,801 · 2025: $3,823.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,972 · Education: $46.91.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,971.74 |
| Education | $46.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,031.18 | 2023-2025 | Caplyta |
| Abbvie INC. | $745.92 | 2023-2025 | |
| Teva Pharmaceuticals USA, INC. | $640.20 | 2023-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Otsuka America Pharmaceutical, INC. | $621.71 | 2023-2025 | Abilify Asimtufii, Rexulti, Abilify Maintena |
| Lundbeck LLC | $604.58 | 2024-2025 | Abilify Asimtufii, Rexulti |
| Alkermes, INC. | $565.03 | 2023-2025 | Aristada, Lybalvi, Aristada Initio |
| Corium, LLC | $499.87 | 2023-2025 | Azstarys |
| Janssen Pharmaceuticals, INC | $440.51 | 2023-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Neurocrine Biosciences, INC. | $367.90 | 2024-2025 | Ingrezza |
| E.R. Squibb & Sons, L.L.C. | $356.97 | 2024-2025 | Cobenfy |
| Axsome Therapeutics, INC. | $203.45 | 2024-2025 | Auvelity, Sunosi |
| Almatica Pharma LLC | $156.22 | 2024-2025 | Loreev Xr |
| Tris Pharma INC | $119.16 | 2023-2025 | Dyanavel Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $118.82 | 2023-2025 | Trintellix |
| Indivior INC. | $106.49 | 2024-2025 | Sublocade, Perseris |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertical Pharmaceuticals, LLC | $77.24 | 2024-2025 | Relexxii |
| Avion Pharmaceuticals | $69.66 | 2023-2024 | Relexxii, Methylphenidate Hydrochloride |
| Collegium Pharmaceutical, INC. | $59.20 | 2025 | Jornay Pm |
| Bausch Health US, LLC | $52.47 | 2024-2025 | Aplenzin |
| Biogen, INC. | $43.67 | 2024-2025 | Zurzuvae |
| Braeburn INC. | $43.61 | 2025 | Brixadi |
| Supernus Pharmaceuticals, INC. | $28.93 | 2024 | Qelbree |
| Idorsia Pharmaceuticals US INC | $24.98 | 2023 | Quviviq |
| Vanda Pharmaceuticals INC. | $22.75 | 2025 | Fanapt |
| Ironshore Pharmaceuticals INC. | $18.13 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Littner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.